{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-018639","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.613078+00:00","generated_at":"2026-06-19T18:00:22.128011+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VYNE Therapeutics completes 1:18 reverse stock split, reducing shares to ~3.25M","bullets":["1:18 reverse stock split effective Feb 10, 2023; shares outstanding drop from 58.5M to ~3.25M.","Board approved final ratio on Feb 8; stockholders authorized range 1:10–1:25 at Jan 12 special meeting.","No fractional shares issued; cash payments in lieu. Trading on split-adjusted basis begins Feb 13, 2023.","CUSIP changes to 92941V 308; all stock options and warrants adjusted proportionally with higher exercise price."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-018639","json":"https://secwatch.observer/filing/0001104659-23-018639.json","markdown":"https://secwatch.observer/filing/0001104659-23-018639.md","text":"https://secwatch.observer/filing/0001104659-23-018639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923018639/0001104659-23-018639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923018639/tm236109d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T18:00:22.128011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2efeec53abcfd6b2bd9be6b792c8ab55a9067f3","claim":"VYNE Therapeutics Inc.: Effected a one-for-eighteen reverse stock split of common stock via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-02-10).","evidence_excerpt":"On February 10, 2023, VYNE Therapeutics Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect a one-for-eighteen (1:18) reverse stock split of its outstanding common stock, effective as of February 10, 2023 (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923018639/0001104659-23-018639-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-02-10"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}